Literature DB >> 27330765

Curative resection for leiomyosarcoma of the descending mesocolon with metachronous liver metastasis: A case report and literature review.

Takaharu Kato1, Hiroshi Noda2, Iku Abe2, Sergio Alonso3, Nobu Yokoyama2, Toshiki Rikiyama2.   

Abstract

Mesenteric leiomyosarcoma is a rare disease with poor prognosis. Previously, mesenteric leiomyosarcoma was not differentiated from gastrointestinal stromal tumor (GIST), which is the most common mesenchymal tumor of the gastrointestinal tract, and several cases of GIST may have been misclassified as mesenteric leiomyosarcoma. Thus, the actual clinicopathological characteristics of mesenteric leiomyosarcomas remain unclear. We herein describe a case of leiomyosarcoma arising in the descending mesocolon in a patient who developed metachronous liver metastasis. A 76-year-old woman reported a mass in her left upper abdomen. Computed tomography imaging revealed a low-density tumor adjacent to the descending colon. The patient underwent surgery and the tumor was resected along with part of the descending colon. Immunohistochemical differential diagnosis revealed that the tumor was positive for smooth muscle actin and desmin, and negative for CD117 (c-KIT) and S-100, which are characteristic of gastrointestinal leiomyosarcoma. A single liver metastasis developed 24 months after the operation. The patient underwent curative resection of the metastatic lesion. Sixteen months following surgery for the liver metastasis and 40 months after the initial removal of the primary lesion, the patient remains disease-free. The prognosis of leiomyosarcoma remains poor and standardized chemotherapy for this rare disease has not yet been established. Early diagnosis and surgical removal of the tumor is the only potentially curative option for liver metastasis of mesenteric leiomyosarcoma.

Entities:  

Keywords:  immunohistochemical analysis; leiomyosarcoma; liver metastasis; mesocolon; surgical resection

Year:  2016        PMID: 27330765      PMCID: PMC4906988          DOI: 10.3892/mco.2016.874

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


  13 in total

1.  Leiomyosarcoma of the Mesentery.

Authors:  W Derechin; S Wolfe
Journal:  Can Med Assoc J       Date:  1956-12-15       Impact factor: 8.262

2.  Ileal Mesenteric Leiomyosarcoma--Report of a Rare Neoplasm.

Authors:  Senjuti Dasgupta; Sudipta Chakrabarti; Suman Ghosh; Shikha Das
Journal:  J Gastrointest Cancer       Date:  2016-03

3.  Primary leiomyosarcoma of the mesentery in two sisters: clinical and molecular characteristics.

Authors:  Magdalena Koczkowska; Beata S Lipska; Joanna Grzeszewska; Janusz Limon; Wojciech Biernat; Jacek Jassem
Journal:  Pol J Pathol       Date:  2013-04       Impact factor: 1.072

4.  An unusual abdominal tumor--leiomyosarcoma of the mesentery: a case report.

Authors:  Catherine J Simonovich; John M Hardman; James J Navin; Jennifer Jacobs; Neil Fergusson
Journal:  Hawaii Med J       Date:  2006-01

5.  Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.

Authors:  S Hirota; K Isozaki; Y Moriyama; K Hashimoto; T Nishida; S Ishiguro; K Kawano; M Hanada; A Kurata; M Takeda; G Muhammad Tunio; Y Matsuzawa; Y Kanakura; Y Shinomura; Y Kitamura
Journal:  Science       Date:  1998-01-23       Impact factor: 47.728

6.  Contemporary management and classification of hepatic leiomyosarcoma.

Authors:  Mazin O Hamed; Keith J Roberts; William Merchant; J Peter A Lodge
Journal:  HPB (Oxford)       Date:  2014-11-24       Impact factor: 3.647

7.  Factors affecting the outcome of patients with metastatic leiomyosarcoma treated with doxorubicin-containing chemotherapy.

Authors:  N Penel; A Italiano; N Isambert; E Bompas; G Bousquet; F Duffaud
Journal:  Ann Oncol       Date:  2009-10-30       Impact factor: 32.976

8.  Gemcitabine with paclitaxel therapy against mesocolic leiomyosarcoma: a case report.

Authors:  Tomoaki Mizobe; Yoshito Akagi; Hiroto Ishikawa; Ichitaro Shiratsuchi; Yosuke Oka; Tetsushi Kinugasa; Kouichi Ohshima; Kozo Setojima; Kazuo Shirouzu
Journal:  Anticancer Res       Date:  2013-07       Impact factor: 2.480

9.  Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected].

Authors:  Robert G Maki; J Kyle Wathen; Shreyaskumar R Patel; Dennis A Priebat; Scott H Okuno; Brian Samuels; Michael Fanucchi; David C Harmon; Scott M Schuetze; Denise Reinke; Peter F Thall; Robert S Benjamin; Laurence H Baker; Martee L Hensley
Journal:  J Clin Oncol       Date:  2007-07-01       Impact factor: 44.544

10.  Leiomyosarcoma of the mesentry, a rare mesentric tumour.

Authors:  Abbas K Sidhic; Mannalakkal Ranjith; Karat Parambil Abid Ali; Pappala Rahul Tej
Journal:  Int J Surg Case Rep       Date:  2014-12-31
View more
  1 in total

1.  DOG1-Positive Primary Mesenteric Leiomyosarcoma: Report of a Case and Review of the Literature.

Authors:  Nektarios Koufopoulos; Vasileia Damaskou; Vasiliki Siozopoulou; Panagiotis Kokoropoulos; Alina-Roxani Gouloumis; Nikolaos Arkadopoulos; Ioannis G Panayiotides
Journal:  Cureus       Date:  2022-05-23
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.